N/A N=48 Embolization in Splenic Trauma
Trauma to the Spleen
Primary: Number of Participants Who Were Enrolled Within 18 Months of Study Initiation — 23; 23 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy
Colorectal Carcinoma
Primary: Freedom From Serious Adverse Events Rate — 18 Participants
Phase 2 N=45 Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery
Liver Cancer
Primary: Time to Progression (TTP) in Patients Treated With TACE and Y90 — 26; 6.8 Months — p=0.007
Phase 2 N=15 Prostate Embolization for Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Number of Participants With Bladder or Rectal Injury — 0 Participants
Phase 2 N=42 Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
Colorectal Neoplasms · Neuroendocrine Tumors · Cholangiocarcinoma
Primary: Number of Participants With Adverse Events — 42 participants
Phase 2 N=101 Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma
Hepatocellular Carcinoma · Liver Cancer · Hepatoma
Primary: Response to Treatment by RECIST Criteria — 3; 3; 48; 47 Participants
N/A N=13 Taiwan ACE Beads for Hepatoma Embolization Therapy
Cancer of Liver
Primary: Patients Survival (Safety) — 12 Participants
N/A N=25 Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Freedom From Serious Adverse Event (SAE) at 30days — 22 participants
N/A N=499 Embosphere® PROstate Post Market Study
Benign Prostatic Hyperplasia · Lower Urinary Tract Symptoms
Primary: Long-term Effectiveness of Prostatic Artery Embolization (PAE) With Embosphere Microspheres as Assessed by the International Prostate Symptom Score (IPSS). — -11.1…
N/A N=40 Genicular Artery Embolization for the Treatment of Knee Osteoarthritis
Knee Osteoarthritis · Degenerative Joint Disease of Knee
Primary: Number of Participants Experiencing Treatment-related Adverse Events, as a Measure of Safety — 1; 7; 2 Participants
N/A N=50 3D Rotational CT Angiogram With Embolization Guidance and CBCT in Prostatic Artery Embolization
Enlarged Prostate
Primary: Time for Prostatic Artery Catheterization — 273.40; 181.71; 206.38; 155.96 seconds
Phase 2 N=50 Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
Liver Neoplasms
Primary: Time to Progression (TTP) of the Treated Lesion(s) According to RECIST Criteria
N/A N=38 Geniculate Artery Embolization for Treatment of Osteoarthritis
Osteoarthritis
Primary: Percentage Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Pain Score — -50.1 Percentage change
Phase 2 N=50 Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
Liver Cancer · Metastatic Cancer
Primary: Time to Progression — 2.3; 7.2 Months
N/A N=9 Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Prostatic Hyperplasia, Benign · Enlarged Prostate With Lower Urinary Tract Symptoms
Primary: Number of Participants With Adverse Events — 3 Participants
N/A N=45 Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia (BPH)
Primary: The Primary Objective is to Evaluate the Safety of Prostate Artery Embolization (PAE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) Attributed to Benign…
Phase 2 N=39 Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
Neuroendocrine Tumor · Islet Cell Tumor
Primary: Percentage of Participants With Progression Free Survival (PFS) at 12 Months — 66 percentage of participants
N/A N=99 An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres
Uterine Fibroid · Arteriovenous Malformations · Hypervascular Tumors
Primary: Procedural Success — 70; 16; 7; 6 Participants
N/A N=28 Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres
Benign Prostatic Hyperplasia (BPH)
Primary: Number of Reported Treatment-related Adverse Events (AE) as Assessed by NCI CTCAE Grading Scale . — 6; 10; 0; 0 events — p=0.05
N/A N=20 Bariatric Embolization of Arteries for the Treatment of Obesity
Morbid Obesity
Primary: Percent Weight Change — 11.5 percentage of excess weight loss
N/A N=11 Geniculate Artery Embolization for Knee Osteoarthritis
Knee Osteoarthritis
Primary: Change in KOOS Pain Score — 33 score on a scale — p=0.00041
N/A N=11 HDE Use Protocol of TheraSphere for Treatment of Unresectable HCC
Hepatocellular Carcinoma
Primary: Progression — 11 participants
Phase 3 N=28 A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation
Hypervascular Tumor and Arteriovenous Malformation
Primary: Success Rate of Embolization in the Target Vessel — 100; 96.4 Percentage of participants
Phase 2 N=44 Superior Hypogastric Nerve Block for Pain Control Post-uterine Fibroid Embolization
Leiomyoma
Primary: mg Equivalent Morphine Used Until Discharge From Recovery Room to Control Pain Level Below 4/10 (VAS) — 11; 5.1 mg
Phase 4 N=60 A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)
Leiomyoma · Uterine Fibroids · Uterine Neoplasms
Primary: Number of Participants With Fibroid Devascularization Measured by Contrast Enhanced Magnetic Resonance Imaging (MRI) — 29; 29 participants
N/A N=101 EmboCube Gelatin Embolization to Control Bleeding or Hemorrhaging
Hemorrhage · Bleeding Hemorrhage
Primary: Number of Participants With Clinical Success: Cessation of Bleeding up to 24 Hours — 100 Participants
Phase 4 N=124 A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures
Congenital Hemangioma · Hemangioendothelioma · Angiosarcoma
Primary: Adverse Drug Reactions During the Embolization Procedure — 0 Participants
N/A N=3 Safety and Effectiveness of OCL 503 in the Treatment of Women With Leiomyomata
Leiomyomata
Primary: Number of Participants With Serious Adverse Events — 0; 0 Participants
Phase 2 N=53 Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
Uveal Melanoma · Liver Metastases
Primary: Response of Liver Metastases — 0; 0; 5; 3 participants
N/A N=376 Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA
Chronic Subdural Hematoma
Primary: Residual or Re-accumulation of the Chronic Subdural Hematoma (cSDH) (Greater Than [>] 10 Millimeter [mm]) as Assessed by an Independent Core Laboratory OR Any…